|Videos|August 2, 2016

How Do Microbes Build Resistance to Metals?

Jeff Boyd, PhD, assistant professor of Biochemistry and Microbiology at Rutgers School of Environmental and Biological Sciences, explains the metal-resistance processes of microbes.

Jeff Boyd, PhD, assistant professor of Biochemistry and Microbiology at Rutgers School of Environmental and Biological Sciences, explains the metal-resistance processes of microbes.

Interview Transcript (slightly modified for readability).

“How do microbes acquire resistance or build resistance to metals, or copper specifically? Well there [are] a number of different mechanisms. Remember, copper, if it gets inside the cell, it becomes highly toxic. It also likes to interact with the membrane, which is on the outside of the cell.

Not surprisingly, microbes have evolved the mechanisms to be able to prevent [copper] from getting inside of the cell. [Microbes] can produce proteins on the outside of the cell which will bind copper and disallow it from interacting with the membrane itself. If [copper] does get inside the cell, there [are] small proteins [that] can bind that copper, buffer it, sequester it, and not allow it to interact with different cellular macromolecules.

Another mechanism is, if copper is in the cytosol, [microbes] can produce pumps that’ll pump that copper outside of the cell. The addition of all of these different [mechanisms], the addition of buffering the cytosol, preventing copper from interacting with macromolecules, pumping copper to the outside of the cell if it does get in the cell, and binding the copper so [that] it can’t interact with the membrane, can prevent the organism from succumbing to a copper intoxication.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.